A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer

被引：12
作者：
Tan, Weige [1 ,2 ,3 ]
Luo, Wei [1 ,2 ]
Jia, Weijuan [1 ,2 ]
Liang, Gehao [1 ,2 ]
Xie, Xinhua [4 ]
Zheng, Wenbo [3 ]
Song, Erwei [1 ,2 ,5 ]
Su, Fengxi [1 ,2 ]
Gong, Chang [1 ,2 ]
机构：
[1] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou, Guangdong, Peoples R China
[3] Guangzhou Med Univ, Affiliated Hosp 1, Dept Breast Surg, Guangzhou, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China
[5] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
来源：
ONCOTARGET | 2016年 / 7卷 / 52期
基金：
美国国家科学基金会;
关键词：
breast cancer; pathologic complete response; neoadjuvant chemotherapy; Nottingham prognostic index; IHC4; 21-GENE RECURRENCE SCORE; DECISION-MAKING; THERAPY; IMPACT; ASSAY; CYCLOPHOSPHAMIDE; CLASSIFICATION; SUBTYPES;
D O I：
10.18632/oncotarget.13549
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pathologic complete response (pCR) prediction after neoadjuvant chemotherapy (NAC) is important for clinical decision-making in breast cancer. This study investigated the predictive value of Nottingham prognostic index (NPI), Immunohistochemical four (IHC4) score and a new predictive index combined with them in estrogen-positive (ER+) breast cancer following NAC. We retrospectively gathered clinical data of 739 ER+ breast cancer patients who received NAC from two cancer centers. We developed a new predictive biomarker named NPI+IHC4 to predict pCR in ER+ breast cancer in a training set (n=443) and validated it in an external validation set (n=296). The results showed that a lower IHC4 score, NPI and NPI+IHC4 were significantly associated a high pCR rate in the entire cohort. In the study set, NPI+IHC4 showed a better sensitivity and specificity for pCR prediction (AUC 0.699, 95% CI 0.626-0.772) than IHC4 score (AUC 0.613, 95% CI 0.533-0.692), NPI (AUC 0.576, 95% CI 0.494-0.659), tumor size (AUC 0.556, 95% CI 0.481-0.631) and TNM stage (AUC 0.521, 95% CI 0.442-0.601). In the validation set, NPI+ IHC4 had a better predictive value for pCR (AUC 0.665, 95% CI 0.579-0.751) than IHC4 score or NPI alone. In addition, ER+ patients with lower IHC4, NPI and NPI+ IHC4 scores had significantly better DFS in both study and validation sets. In summary, NPI+ IHC4 can predict pCR following NAC and prognosis in ER+ breast cancer, which is cost-effect and potentially more useful in guiding decision-making regarding NAC in clinical practice. Further validation is needed in prospective clinical trials with larger cohorts of patients.
引用
收藏
页码：87312 / 87322
页数：11
相关论文
共 34 条
[21]   Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States [J].
Mougalian, Sarah S. ;
Soulos, Pamela R. ;
Killelea, Brigid K. ;
Lannin, Donald R. ;
Abu-Khalaf, Maysa M. ;
DiGiovanna, Michael P. ;
Sanft, Tara B. ;
Pusztai, Lajos ;
Gross, Cary P. ;
Chagpar, Anees B. .
CANCER, 2015, 121 (15) :2544-2552
[22]   A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [J].
Paik, S ;
Shak, S ;
Tang, G ;
Kim, C ;
Baker, J ;
Cronin, M ;
Baehner, FL ;
Walker, MG ;
Watson, D ;
Park, T ;
Hiller, W ;
Fisher, ER ;
Wickerham, DL ;
Bryant, J ;
Wolmark, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2817-2826
[23]   Breast Cancer 2 Gene expression profiling in breast cancer: classification, prognostication, and prediction [J].
Reis-Filho, Jorge S. ;
Pusztai, Lajos .
LANCET, 2011, 378 (9805) :1812-1823
[24]   Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer [J].
Ring, AE ;
Smith, IE ;
Ashley, S ;
Fulford, LG ;
Lakhani, SR .
BRITISH JOURNAL OF CANCER, 2004, 91 (12) :2012-2017
[25]   Validation of existing and development of new prognostic classification schemes in node negative breast cancer [J].
Sauerbrei, W ;
Hubner, K ;
Schmoor, C ;
Schumacher, M .
BREAST CANCER RESEARCH AND TREATMENT, 1997, 42 (02) :149-163
[26]   Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer [J].
Schott, Anne F. ;
Hayes, Daniel F. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) :1747-1749
[27]   Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population [J].
Sgroi, Dennis C. ;
Sestak, Ivana ;
Cuzick, Jack ;
Zhang, Yi ;
Schnabel, Catherine A. ;
Schroeder, Brock ;
Erlander, Mark G. ;
Dunbier, Anita ;
Sidhu, Kally ;
Lopez-Knowles, Elena ;
Goss, Paul E. ;
Dowsett, Mitch .
LANCET ONCOLOGY, 2013, 14 (11) :1067-1076
[28]   Repeated observation of breast tumor subtypes in independent gene expression data sets [J].
Sorlie, T ;
Tibshirani, R ;
Parker, J ;
Hastie, T ;
Marron, JS ;
Nobel, A ;
Deng, S ;
Johnsen, H ;
Pesich, R ;
Geisler, S ;
Demeter, J ;
Perou, CM ;
Lonning, PE ;
Brown, PO ;
Borresen-Dale, AL ;
Botstein, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (14) :8418-8423
[29]   The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients [J].
Stemmer, Salomon M. ;
Klang, Shmuel H. ;
Ben-Baruch, Noa ;
Geffen, David B. ;
Steiner, Mariana ;
Soussan-Gutman, Lior ;
Merling, Shahar ;
Svedman, Christer ;
Rizel, Shulamith ;
Lieberman, Nicky .
BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (01) :83-92
[30]   Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes [J].
von Minckwitz, Gunter ;
Untch, Michael ;
Blohmer, Jens-Uwe ;
Costa, Serban D. ;
Eidtmann, Holger ;
Fasching, Peter A. ;
Gerber, Bernd ;
Eiermann, Wolfgang ;
Hilfrich, Joern ;
Huober, Jens ;
Jackisch, Christian ;
Kaufmann, Manfred ;
Konecny, Gottfried E. ;
Denkert, Carsten ;
Nekljudova, Valentina ;
Mehta, Keyur ;
Loibl, Sibylle .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) :1796-1804
1234